Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral Dosing study, which evaluated the safety and efficacy of the oral formulation of ...
Viking Therapeutics, Inc. remains a Buy as VK2735 is arguably the leading GLP-1 obesity drug candidate outside of Eli Lilly and Novo Nordisk's pipelines. VKTX's pivotal VANQUISH Phase 3 injectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results